Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24098231 | 0.92 | ALDH1A1 (0.42) | KISS1RKMT2AMEN1SMN1; SMN2CNR1 | |
| SCHEMBL24330010 | 0.88 | CNR1 (0.45) | KMT2ASMN1; SMN2CNR1ALDH1A1LMNA | |
| SCHEMBL24654179 | 0.82 | KDM4E (0.45) | KISS1RKMT2AMEN1SMN1; SMN2CNR1 | |
| SCHEMBL24330011 | 0.82 | KMT2A (0.39) | KISS1RKMT2AMEN1SMN1; SMN2CNR1 | |
| SCHEMBL23589881 | 0.81 | TP53 (0.41) | KMT2AMEN1SMN1; SMN2CNR1TP53 | |
| SCHEMBL16297541 | 0.81 | KISS1R (0.47) | KISS1RKMT2AMEN1SMN1; SMN2CNR1 | |
| SCHEMBL23133068 | 0.80 | KMT2A (0.40) | KISS1RKMT2AMEN1SMN1; SMN2CNR1 | |
| SCHEMBL19161331 | 0.79 | KMT2A (0.43) | KISS1RKMT2AMEN1SMN1; SMN2CNR1 | |
| SCHEMBL16248615 | 0.79 | ALDH1A1 (0.57) | KMT2AMEN1SMN1; SMN2CNR1TP53 | |
| SCHEMBL14049277 | 0.79 | MEN1 (0.67) | KMT2AMEN1SMN1; SMN2CNR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | KISS1R 4351/4885KMT2A 2641/4885MEN1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.